Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This is a phase 1b/2, open-label, single arm study to evaluate if enasidenib is safe and
effective in improving anemia and decreasing transfusion needs in subjects diagnosed with
lower risk myelodysplastic syndrome (MDS) or nonproliferative chronic myelomonocytic leukemia
(CMML) without a mutation in isocitrate dehydrogenase type 2 (IDH2 wildtype). Other
objectives include assessment of improvements in platelet production and characterization of
the mechanism of action of enasidenib in enhancing endogenous erythropoiesis.